Dr. Wolfgang Berger

Dr. Wolfgang Berger has had extensive work experience in various roles in the pharmaceutical industry. Dr. Wolfgang is currently serving as the Head of Clinical Operations at SOTIO since 2021. Prior to that, they worked at Affimed as the Program Head from 2020 to 2021, where they were responsible for the complete AFM13 immune-oncology product development program.

From 2015 to 2020, Dr. Berger held the position of Managing Director at IgNova GmbH, a biopharmaceutical start-up company. Dr. Wolfgang'sresponsibilities included the development of the company's structure, strategic planning, exploration of patent opportunities, and performing merger and acquisition activities. Dr. Wolfgang was also involved in global development projects and clinical development strategies.

Before that, they served as the Head of Global Clinical Research at Heel GmbH from 2009 to 2014, where they were responsible for all clinical research projects globally. Dr. Wolfgang also worked as the Director of Clinical Development at Newron Pharmaceuticals SpA from 2008 to 2009 and as a Quality Improvement Manager at UCB in 2007.

Dr. Berger's earlier experiences include working as a Senior Clinical Trial Manager at Schwarz Biosciences from 2001 to 2007, where they successfully led the drug development of the dopamine agonist "rotigotine" in the indications of Restless Legs Syndrome and Parkinson's Disease. Dr. Wolfgang also worked as a Clinical Project Manager at Roche from 1999 to 2001, where they managed oncology trials, and as a Clinical Project Leader at AFA from 1991 to 1999.

Dr. Wolfgang Berger received their Ph.D. in Psychology from the University of Cologne in 1987, having attended from 1978 to 1987.